ZA202203680B - Selective inhibitors of protein arginine methyltransferase 5 (prmt5) - Google Patents
Selective inhibitors of protein arginine methyltransferase 5 (prmt5)Info
- Publication number
- ZA202203680B ZA202203680B ZA2022/03680A ZA202203680A ZA202203680B ZA 202203680 B ZA202203680 B ZA 202203680B ZA 2022/03680 A ZA2022/03680 A ZA 2022/03680A ZA 202203680 A ZA202203680 A ZA 202203680A ZA 202203680 B ZA202203680 B ZA 202203680B
- Authority
- ZA
- South Africa
- Prior art keywords
- prmt5
- selective inhibitors
- protein arginine
- arginine methyltransferase
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962902322P | 2019-09-18 | 2019-09-18 | |
| PCT/US2020/051563 WO2021055797A1 (en) | 2019-09-18 | 2020-09-18 | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202203680B true ZA202203680B (en) | 2025-12-17 |
Family
ID=72717922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/03680A ZA202203680B (en) | 2019-09-18 | 2022-03-30 | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12414953B2 (enExample) |
| EP (1) | EP4031555A1 (enExample) |
| JP (1) | JP7706166B2 (enExample) |
| KR (1) | KR20220065811A (enExample) |
| CN (1) | CN114829370B (enExample) |
| AU (1) | AU2020349553A1 (enExample) |
| BR (1) | BR112022004630A2 (enExample) |
| CA (1) | CA3154566A1 (enExample) |
| IL (1) | IL291417B2 (enExample) |
| MX (1) | MX2022003340A (enExample) |
| WO (1) | WO2021055797A1 (enExample) |
| ZA (1) | ZA202203680B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116211869B (zh) * | 2022-12-07 | 2023-08-01 | 浙江省肿瘤医院 | 含dna损伤修复抑制剂的药物混合物及混合方法、用途 |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
| US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| CA1322628C (en) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
| US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
| US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
| US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
| AR081626A1 (es) * | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| US20170198006A1 (en) * | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2016022605A1 (en) * | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| MX2017010844A (es) | 2015-02-24 | 2017-12-07 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes anticancerosos. |
| MA41827A (fr) * | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton |
| AR104326A1 (es) | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
| TWI870767B (zh) | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| AU2017230658B2 (en) | 2016-03-10 | 2021-03-04 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as PRMT5 inhibitors |
| CN108430987B (zh) * | 2016-06-02 | 2021-06-18 | 上海海雁医药科技有限公司 | Pi3k抑制剂及其药学上可接受的盐和多晶型物及其应用 |
| WO2017218802A1 (en) * | 2016-06-15 | 2017-12-21 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| TN2019000087A1 (en) * | 2016-10-03 | 2020-07-15 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| KR101785870B1 (ko) | 2016-11-03 | 2017-10-13 | 한규락 | 오르골 장치 |
| EP3939986A1 (en) | 2017-08-09 | 2022-01-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2019084470A1 (en) | 2017-10-26 | 2019-05-02 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) |
| AU2019235912B2 (en) | 2018-03-14 | 2024-03-21 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
-
2020
- 2020-09-18 WO PCT/US2020/051563 patent/WO2021055797A1/en not_active Ceased
- 2020-09-18 EP EP20785886.1A patent/EP4031555A1/en active Pending
- 2020-09-18 CA CA3154566A patent/CA3154566A1/en active Pending
- 2020-09-18 AU AU2020349553A patent/AU2020349553A1/en active Pending
- 2020-09-18 JP JP2022517372A patent/JP7706166B2/ja active Active
- 2020-09-18 KR KR1020227012615A patent/KR20220065811A/ko active Pending
- 2020-09-18 CN CN202080074610.XA patent/CN114829370B/zh active Active
- 2020-09-18 IL IL291417A patent/IL291417B2/en unknown
- 2020-09-18 MX MX2022003340A patent/MX2022003340A/es unknown
- 2020-09-18 US US17/761,717 patent/US12414953B2/en active Active
- 2020-09-18 BR BR112022004630A patent/BR112022004630A2/pt unknown
-
2022
- 2022-03-30 ZA ZA2022/03680A patent/ZA202203680B/en unknown
-
2025
- 2025-08-18 US US19/302,476 patent/US20250367205A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7706166B2 (ja) | 2025-07-11 |
| IL291417B2 (en) | 2025-12-01 |
| US12414953B2 (en) | 2025-09-16 |
| CN114829370B (zh) | 2025-10-28 |
| WO2021055797A9 (en) | 2021-04-22 |
| AU2020349553A1 (en) | 2022-04-07 |
| BR112022004630A2 (pt) | 2022-05-31 |
| IL291417B1 (en) | 2025-08-01 |
| WO2021055797A1 (en) | 2021-03-25 |
| JP2022548689A (ja) | 2022-11-21 |
| US20230029094A1 (en) | 2023-01-26 |
| CA3154566A1 (en) | 2021-03-25 |
| MX2022003340A (es) | 2022-06-14 |
| IL291417A (en) | 2022-05-01 |
| CN114829370A (zh) | 2022-07-29 |
| KR20220065811A (ko) | 2022-05-20 |
| EP4031555A1 (en) | 2022-07-27 |
| US20250367205A1 (en) | 2025-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020001598A (es) | Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5). | |
| SA522431915B1 (ar) | Prmt5 مثبطات mta تعاونية مع | |
| ZA202105887B (en) | Selective inhibitor of protein arginine methyltransferase 5 (prmt5) | |
| MX2021005463A (es) | Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1). | |
| ZA202005325B (en) | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) | |
| ZA202006137B (en) | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| PH12019502052A1 (en) | Hepatitis b virus surface antigen inhibitor | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| MY209034A (en) | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors | |
| MX380928B (es) | Inhibidores de kras g12c. | |
| PH12022550338A1 (en) | 2-hydroxycycloalkane-1-carbamoyl derivatives | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
| MX2023003264A (es) | Inhibidores de cdk y su uso como productos fármaceuticos. | |
| PH12021551873A1 (en) | Hydroxypyridoxazepines as nrf2 activators | |
| MX2023007265A (es) | Inhibidores de cdk y su uso como productos farmacéuticos. | |
| PH12022551241A1 (en) | Egfr inhibitors | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| WO2018085833A3 (en) | Selective inhibitors of protein arginine methyl transferase 5 (prmt5) | |
| MX2025014397A (es) | Inhibidores de helicasa de adn recq del sindrome de werner (wrn) | |
| ZA202203680B (en) | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) | |
| WO2025014877A3 (en) | Triazolo wrn inhibitors | |
| WO2025036472A8 (en) | Spirocyclic mta-cooperative prmt5 inhibitor | |
| MX2022013890A (es) | Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos. |